| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -485,883 | -514,388 | -399,897 | -841,811 |
| Depreciation | NaN | 0 | 0 | 418 |
| Share-based compensation | 15,161 | 23,673 | 23,674 | 41,348 |
| Expenses settled in stock | NaN | 0 | 0 | 79,000 |
| Accrued expenses | NaN | -147,901 | -4,063 | -10,216 |
| Prepaid expenses | 1,808 | -24,017 | -24,414 | -56,567 |
| Accounts payable | 33,737 | -219,378 | 63,266 | 55,310 |
| Related party payable | 64,617 | 856,334 | -311,525 | 350,769 |
| Net cash used in (provided by) operating activities | -374,176 | 22,357 | -604,131 | -268,615 |
| Advances from related party | 395,000 | 0 | 610,000 | 347,000 |
| Payments on note payable | 22,546 | 22,820 | 22,819 | 52,090 |
| Net cash used in (provided by) financing activities | 372,454 | -22,820 | 587,181 | 294,910 |
| (decrease) increase in cash | -1,722 | -463 | -16,950 | 26,295 |
| Cash, beginning of period | 13,929 | 14,391 | 5,046 | NaN |
| Cash, end of period | 12,207 | 13,929 | 14,391 | NaN |
Accustem Sciences Inc. (ACUT)
Accustem Sciences Inc. (ACUT)